267 related articles for article (PubMed ID: 28881031)
1. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
van Tilborg M; Lieveld FI; Smolders EJ; van Erpecum KJ; de Kanter CTMM; Maan R; van der Valk M; Arends JE; Dofferhoff ASM; Blokzijl H; Bijmolen M; Drenth JPH; de Knegt RJ; Burger DM;
Aliment Pharmacol Ther; 2017 Nov; 46(9):864-872. PubMed ID: 28881031
[TBL] [Abstract][Full Text] [Related]
2. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
4. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
5. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
[TBL] [Abstract][Full Text] [Related]
7. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
Piedoux S; Monnet E; Piroth L; Montange D; Royer B; Thevenot T; Kantelip JP; Di Martino V; Muret P;
Antivir Ther; 2011; 16(8):1317-26. PubMed ID: 22155913
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
[TBL] [Abstract][Full Text] [Related]
13. Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome.
van Vlerken LG; de Kanter CT; Boland GJ; van Loon AM; van Soest H; Koek GH; Drenth JP; Siersema PD; van Erpecum KJ; Burger DM
Ther Drug Monit; 2013 Aug; 35(4):546-51. PubMed ID: 23851908
[TBL] [Abstract][Full Text] [Related]
14. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
15. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
[TBL] [Abstract][Full Text] [Related]
17. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Ohya K; Akuta N; Suzuki F; Fujiyama S; Kawamura Y; Kominami Y; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2018 May; 90(5):919-925. PubMed ID: 29315652
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
Pol S; Sulkowski MS; Hassanein T; Gane EJ; Liu L; Mo H; Doehle B; Kanwar B; Brainard D; Subramanian GM; Symonds WT; McHutchison JG; Nahass RG; Bennett M; Jacobson IM
Hepatology; 2015 Jul; 62(1):129-34. PubMed ID: 25847509
[TBL] [Abstract][Full Text] [Related]
19. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
Yada M; Miyazaki M; Tanaka K; Masumoto A; Motomura K
World J Gastroenterol; 2018 Apr; 24(13):1478-1485. PubMed ID: 29632428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
